Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy

Inclusion Criteria15

• Male or female, age \>= 18 years, with life expectancy of at least 12 weeks.
• Patients with histologically documented metastatic (stage IV) non-small cell lung cancer.
• Subjected to driving genes examination including EGFR, ALK and ROS1.
• Achieve complete response (CR)/partial response (PR)/stable disease (SD) after front line systemic treatment (chemotherapy, targeted therapy or immunological checkpoint inhibitors).
• Total metastatic lesions is limited to five.
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of \<= 2.
• Patients must have measurable disease according to the RECIST (version 1.1) criteria.
• Adequate organ function as defined by the following criteria:
• Liver function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<= 2.5 upper limit of normal (ULN) in the absence of liver metastases or up to 5 ULN in case of liver metastases. Total bilirubin \<= 1.5 ULN.
• Bone marrow function: Granulocyte count \>= 1,500/mm3 and platelet count ≥100,000/mm3 and hemoglobin \>= 80g/dl.
• Renal function: serum creatinine \<= 1.5 ULN or creatinine clearance \>= 60 ml/min. (based on modified Cockcroft-Gault formula).
• Adequate coagulating function.
• For all females of childbearing potential a negative serum/urine pregnancy test must be obtained within 48 hours before enrollment. Postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Males must agree to use effective contraception during the study period and for at least 12 weeks after completion of the study treatment.
• Written (signed) informed Consent to participate in the study.
• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.